MR Solutions Now Offers the Widest Range of Preclinical Nuclear Medicine Imaging Systems of Any Manufacturer

A world leader in helium free MRI systems for preclinical research laboratories MR Solutions has now developed the largest and most advanced range of preclinical nuclear medicine combination systems of any manufacturer.

The PET and SPECT nuclear systems can be stand-alone or clipped onto the front of any of MR Solutions’ extensive range of high field, liquid helium free MRI systems or its range of cutting edge CT systems. The PET scanners can also be configured to operate as an insert in the bore of all the MRI systems providing simultaneous imaging. The PET and SPECT scanners range in size from 15 g for small rodents up to 12 kgs for larger animals.

The PET insert (for simultaneous scanning) or PET clip-on module (for sequential scanning) use the latest silicon photomultiplier (SiPM) technology. This provides true depth of interaction (DOI) from hardware with two pixelated layers of scintillator crystal with different matrices providing <0.8 mm resolution. All of the PET modules are fitted with MR Solution’s superior ringless detector technology.

The SPECT clip-on modules are available in different configurations with a range of transaxial views allowing optimal imaging for different sized animals.

All of MR Solution’s preclinical scanning systems are fitted with the easy to use Preclinical Scan multimodality interface. This software provides access to all the functions – MRI/CT/PET/SPECT.  Advanced functionalities are available for experienced users.

Both the CT and MRI scanners include a motorized animal bed allowing the animal to be scanned without any manual input from the operator. These precision animal beds are compatible across all of MR Solutions’ CT and MRI ranges.

MR Solutions, based in the UK, has over 30 years’ experience and in excess of 2000 installations including spectrometer sales across the world. MR Solutions holds the prestigious Queen’s Award for Enterprise awards, achieving this for Innovation in 2016 and 2019 and for International Trade in 2017. MR Solutions also has offices in the US and technical support in all the major centers.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”